Current Report on Form 8-K

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 5, 2007


Health Discovery Corporation
(Exact name of registrant as specified in charter)


Texas
333-62216
74--3002154
(State of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)


2 East Bryan Street, Savannah, GA 31401
(Address of principal executive offices / Zip Code)


912-443-1987
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act.
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
o
Pre-commencement communications pursuant to Rule 14d—2(b) under the Exchange Act.
o
Pre-commencement communications pursuant to Rule 13e—4(c) under the Exchange Act.
 



Item 1.01 Entry into a Material Definitive Agreement.


On July 5, 2007, Health Discovery Corporation (the “Company”) entered into a patent license and settlement agreement (the “Agreement”) with Ciphergen Biosystems, Inc. (“Ciphergen”) in connection with the pending litigation styled Health Discovery Corporation v. Ciphergen Biosystems, Inc. Case No. 07-00285-CRB, before the United States District Court for the Northern District of California. In consideration for entering into the Agreement, Ciphergen agreed to pay the Company $600,000. Additionally, the Company agreed to grant a license to use the Company’s SVM software in conjunction with a SELDI-based mass spectrometer. Pursuant to the terms of the Agreement, each party agreed to voluntarily dismiss with prejudice any and all claims it has against the other party.

 
 

 
2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
     
  HEALTH DISCOVERY CORPORATION
 
 		  
 		  
 
Dated: July 9, 2007 By:   /s/ Daniel Furth
 
Daniel Furth
Principal Financial Officer
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3